Prot# CSTI571H2201: A Phase II, Open-Label, Multi-Centre, Single-Arm Study, Evaluating the Efficacy of Glivec® plus Hydroxyurea (HU) in Patients with Progressive Giloblastoma Multiforme (GBM), Not Receiving Enzyme Inducing Anticonvulsant Drugs (